<DOC>
	<DOC>NCT00145574</DOC>
	<brief_summary>This study will evaluate the lipid-lowering effect and safety of colesevelam therapy administered to heterozygous familial pediatric patients 10 through 17 years of age who are on a stable dose of a pediatric-approved statin monotherapy (atorvastatin, lovastatin, simvastatin or pravastatin), or who are treatment naive to lipid-lowering therapy.</brief_summary>
	<brief_title>Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Colesevelam Hydrochloride</mesh_term>
	<criteria>Male or female patients Ages 10 to 17 years inclusive Diagnosis of heterozygous familial hypercholesterolemia On a stable dose of statin monotherapy or are treatment naive to lipid lowering agents On a lowcholesterol diet Patients should not have serious concomitant conditions that could interfere with the analysis of the results or that could interfere with the wellbeing of the patients</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>hypercholesterolemia</keyword>
	<keyword>colesevelam</keyword>
</DOC>